Literature DB >> 12668149

Cytoskeletal protein degradation and neurodegeneration evolves differently in males and females following experimental head injury.

Nancy C Kupina1, Megan R Detloff, Walter F Bobrowski, Bradley J Snyder, Edward D Hall.   

Abstract

The resulting neuropathological degeneration that occurs following a traumatic brain injury (TBI) is a consequence of both immediate and secondary neurochemical sequelae. Proteolysis of cytoskeletal proteins, triggered by calcium-mediated events, is believed to be a particularly significant contributor to TBI-induced neuronal death. To date, efforts to associate cytoskeletal degradation and neurodegeneration in TBI have been primarily qualitative or semiquantitative. The objectives of this study were (1). to quantitatively describe, over a posttraumatic time course, the relationship and mechanisms of cytoskeletal degradation (Western blot) and neurodegeneration (silver staining) in male and female mice following a moderately severe weight-drop impact-acceleration head injury; (2). to evaluate gender differences in the response to TBI; and (3). to examine the potential therapeutic window for future pharmacological treatment strategies. In male and female mice, we report a close correlation in the time courses of neurofilament M protein degradation and alpha-spectrin breakdown products (SBDP 150 and 145) with the peak magnitude of neurodegeneration, as quantified by silver staining. Evidence from the increased patterns of SBDPs suggests that both calpain and caspase-3 are involved. In general, males incurred peak protein degradation and neurodegeneration within 3 days after injury, while in females this did not occur until 14 days. The neuroprotective effects of estrogen are believed to be key factors in the superior outcome of female vs male mice following TBI. In mice, the therapeutic window of opportunity for pharmacological intervention aimed at limiting cytoskeletal degradation might be as much as 24 h following injury. Evidence of a protracted time course of cytoskeletal degradation, especially in females, suggests a potential for an extended treatment-duration following TBI.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12668149     DOI: 10.1016/s0014-4886(02)00048-1

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  32 in total

1.  A substance P antagonist improves outcome in female Sprague Dawley rats following diffuse traumatic brain injury.

Authors:  Frances Corrigan; Anna Leonard; Mounir Ghabriel; Corinna Van Den Heuvel; Robert Vink
Journal:  CNS Neurosci Ther       Date:  2012-06       Impact factor: 5.243

2.  Verapamil prevents, in a dose-dependent way, the loss of ChAT-immunoreactive neurons in the cerebral cortex following lesions of the rat nucleus basalis magnocellularis.

Authors:  Miroljub Popović; Maria Caballero-Bleda; Natalija Popović; Luis Puelles; Thomas van Groen; Menno P Witter
Journal:  Exp Brain Res       Date:  2005-11-23       Impact factor: 1.972

3.  Involvement of Stat3 in mouse brain development and sexual dimorphism: a proteomics approach.

Authors:  Fabio Di Domenico; Gabriella Casalena; Rukhsana Sultana; Jian Cai; William M Pierce; Marzia Perluigi; Chiara Cini; Alessandra Baracca; Giancarlo Solaini; Giorgio Lenaz; Jia Jia; Suzan Dziennis; Stephanie J Murphy; Nabil J Alkayed; D Allan Butterfield
Journal:  Brain Res       Date:  2010-09-25       Impact factor: 3.252

4.  A pharmacological analysis of the neuroprotective efficacy of the brain- and cell-permeable calpain inhibitor MDL-28170 in the mouse controlled cortical impact traumatic brain injury model.

Authors:  Stephanie N Thompson; Kimberly M Carrico; Ayman G Mustafa; Mona Bains; Edward D Hall
Journal:  J Neurotrauma       Date:  2010-12       Impact factor: 5.269

5.  Role of gender in outcome after traumatic brain injury and therapeutic effect of erythropoietin in mice.

Authors:  Ye Xiong; Asim Mahmood; Dunyue Lu; Changsheng Qu; Anton Goussev; Timothy Schallert; Michael Chopp
Journal:  Brain Res       Date:  2007-10-31       Impact factor: 3.252

6.  Pharmacological inhibition of lipid peroxidation attenuates calpain-mediated cytoskeletal degradation after traumatic brain injury.

Authors:  Ayman G Mustafa; Juan A Wang; Kimberly M Carrico; Edward D Hall
Journal:  J Neurochem       Date:  2011-03-22       Impact factor: 5.372

7.  Estrogen or estrogen receptor agonist inhibits lipopolysaccharide induced microglial activation and death.

Authors:  Joshua A Smith; Arabinda Das; Jonathan T Butler; Swapan K Ray; Naren L Banik
Journal:  Neurochem Res       Date:  2010-12-03       Impact factor: 3.996

Review 8.  Sex-related responses after traumatic brain injury: Considerations for preclinical modeling.

Authors:  Claudia B Späni; David J Braun; Linda J Van Eldik
Journal:  Front Neuroendocrinol       Date:  2018-05-18       Impact factor: 8.606

9.  Progesterone effects on neuronal ultrastructure and expression of microtubule-associated protein 2 (MAP2) in rats with acute spinal cord injury.

Authors:  Susana L González; Juan José López-Costa; Florencia Labombarda; Maria Claudia González Deniselle; Rachida Guennoun; Michael Schumacher; Alejandro F De Nicola
Journal:  Cell Mol Neurobiol       Date:  2008-06-27       Impact factor: 5.046

10.  Estrogen attenuates glutamate-induced cell death by inhibiting Ca2+ influx through L-type voltage-gated Ca2+ channels.

Authors:  Eric A Sribnick; Angelo M Del Re; Swapan K Ray; John J Woodward; Naren L Banik
Journal:  Brain Res       Date:  2009-04-21       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.